Frankfurt - Delayed Quote EUR
Neural Therapeutics Inc. (M6B.F)
0.0179
0.0000
(0.00%)
As of March 31 at 3:29:01 PM GMT+2. Market Open.
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Ian Campbell M.Sc. | President, CEO, Member of Scientific Impact and Advisory Board & Director | -- | -- | -- |
| Mr. Omar Gonzalez | Chief Financial Officer | -- | -- | -- |
Neural Therapeutics Inc.
77 King Street West
Suite 2905 P.O. Box 121
Toronto, ON M5K 1H1
Canada
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Neural Therapeutics Inc., a drug discovery company, focuses on plant-based active substances. It focuses on San Pedro, a cactus containing mescaline and delivers over-the-counter dietary supplements and psychedelic-based therapeutic medicines to treat serious mental ailments. Neural Therapeutics Inc. was formerly known as Psychedelic Science Corp. and changed its name to Neural Therapeutics Inc. in November 2021. The company was incorporated in 2020 and is headquartered in Toronto, Canada.
Corporate Governance
Neural Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available